Last $0.02 USD
Change Today -0.001 / -5.88%
Volume 24.6K
LTUS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

16 Cheng Zhuang Road

Feng Tai District

Beijing, 100071

China

Phone: 86 10 6389 9868

Fax: 86 10 6389 9867

Lotus Pharmaceuticals Inc. develops, manufactures, and sells pharmaceuticals in China. The company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. Its drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. Valsartan Valsartan: Valsartan is a drug that treats hypertension or high blood pressure. Valsartan works by blocking a substance in the body that causes blood vessels to tighten. As a result, Valsartan relaxes blood vessels. This lowers blood pressure and improves the supply of blood and oxygen to the heart. The company holds manufacturing rights to produce Valsartan. Brimonidine Tartrate Eyes Drops: Brimonidine Tartrate is a drug used to constrict adrenaline receptors, a major step in treating glaucoma. The company sells Brimonidine Tartrate eye drops under its brand name Muxin. It holds manufacturing rights to produce Brimonidine Tartrate. Levofloxacin Lactate for Injection: Levofloxacin is an anti-bacterial drug for the treatment of mild, moderate, and severe infections caused by susceptible trains of the designated microorganisms in the conditions, such as acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, complicated and uncomplicated skin and skin structure infections, complicated and uncomplicated urinary tract infections, and acute pyelonephritis. It sells Levofloxacin Lactate for Injection under its brand name Junxin. The imported product of its kind is manufactured by Japanese pharmaceutical company, Daiichi Pharmaceutical Co. Nicergoline for Injection: Nicergoline for Injection is a national medical insurance product. It is an a-receptor blockage nerve system blood-brain medicine with remarkable curative effect. The company also acts as a wholesale distributor to distribute various pharmaceutical products manufactured by third party manufactures. Yipubishan -Octreotide Acetate Injection Solution: Yipubishan is a national medical insurance product. Yipubishan is an octreotide Acetate Injection solution for the treatment of gastric ulcers. Retail Drugstores The company owns and operates 10 drug stores throughout different districts of Beijing, including Xin Zhong Tai Drugstore; Nan Gong Drugstore; Wan Shou Road Drugstore; He Ping Li Drugstore; Feng Lin Lv Zhou Drugstore; Youth Lake Drugstore; Capital Airport Drugstore; Yong An Zhong Sheng Drugstore; Cheng Zhuang Road Drugstore; and Feng Tai Drugstore. Sales The company has a nationwide sales network to directly and indirectly sell to hospitals, clinics and drugs stores in approximately 30 provinces in China. Competition The company’s competitors include Beijing Venture Biopharma Technology Co., Ltd., Fosun Group Co., Ltd., Zhuhai Lizhu, and Beijing Nohua.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LTUS:US $0.02 USD -0.001

LTUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LTUS.
View Industry Companies
 

Industry Analysis

LTUS

Industry Average

Valuation LTUS Industry Range
Price/Earnings 0.3x
Price/Sales 0.0x
Price/Book 0.0x
Price/Cash Flow 0.3x
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LOTUS PHARMACEUTICALS INC, please visit www.lotuspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.